Tar Heel Capital Acquires 75% Stake in Med-Gastr
Tar Heel Capital Acquires 75% Stake in Med-Gastr, Expands Healthcare Consolidation Strategy in Poland
Investment signals next phase of private healthcare scale-up and early diagnostics in gastroenterology
Tar Heel Capital (THC), a prominent Polish private equity fund, has acquired a 75% majority stake in Centrum Medyczne Med-Gastr, a specialized gastroenterology clinic, as part of its broader strategy to consolidate and modernize private healthcare services in Poland.
The investment reflects THC’s growing footprint in the medical sector, where it has already built multiple national-level healthcare platforms. Med-Gastr becomes the third consolidation platform under THC’s healthcare investment strategy, joining a portfolio of specialized clinics and centers aimed at improving patient access, operational efficiency, and medical innovation.
Subscribe to Startup Digest to stay ahead with the latest news, investments, and must-attend events.
Based in Poland, Med-Gastr is known for its focus on gastrointestinal diagnostics and treatment, with a particular emphasis on early colorectal cancer screening—a medical priority as Poland faces rising rates of digestive system diseases and one of the lowest preventive screening uptakes in the EU.
“This acquisition is part of a long-term strategy to scale regional leaders into national champions in specialized care,” said a representative of Tar Heel Capital. “We see tremendous opportunity in strengthening Poland’s early diagnosis infrastructure, improving medical access, and driving consolidation across fragmented private healthcare markets.”
A Private Equity Platform with Operational Depth
Tar Heel Capital has become one of the most active private equity firms in Poland, with investments spanning healthcare, industrial services, and consumer sectors. Beyond capital, THC provides strategic, financial, and operational support—often taking a hands-on approach to modernizing and scaling companies through digital transformation, brand development, and new market entry.
THC is known not only for its traditional PE arm, but also for its dynamic venture arm: Tar Heel Capital Pathfinder, which partners with founders at the earliest stages of company creation. Pathfinder acts as both a venture capital fund and venture builder, co-founding and funding startups in AI, software, medtech, and e-commerce, often from just a concept or MVP stage. It has supported over 60 projects and generated multiple exits, including a recent 10x CoC return on the mental health platform Wellbee.
The acquisition of Med-Gastr complements THC’s overall strategy: investing across the spectrum of healthcare innovation, from early-stage medtech startups via Pathfinder to growth-stage clinics and diagnostic centers through its private equity arm.
This move also aligns with growing public awareness and government support for early cancer screening initiatives in Poland, particularly amid broader healthcare system reforms and rising private sector participation.
The financial terms of the Med-Gastr transaction were not disclosed. The clinic’s founding shareholders, including the ArKa family foundation, will retain a minority stake and continue to participate in future strategic development.
